Minerva Surgical (NASDAQ:UTRS) versus Vivos (OTCMKTS:RDGL) Financial Survey

Vivos (OTCMKTS:RDGL) and Minerva Surgical (NASDAQ:UTRS) are both small-cap finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.

Earnings & Valuation

This table compares Vivos and Minerva Surgical’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos	$20,000.00	1,404.29	-$2.89 million	N/A	N/A
Minerva Surgical	$50.29 million	0.11	-$34.11 million	($8.21)	-0.08

Vivos has higher earnings, but lower revenue than Minerva Surgical.

Risk & Volatility

Vivos has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Minerva Surgical has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.

Profitability

This table compares Vivos and Minerva Surgical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos	-9,524.89%	N/A	-180.12%
Minerva Surgical	-64.71%	-136.40%	-43.70%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Vivos and Minerva Surgical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos	0	0	0	0	N/A
Minerva Surgical	0	0	0	0	N/A

Minerva Surgical has a consensus price target of $20.00, suggesting a potential upside of 3,049.76%. Given Minerva Surgical’s higher possible upside, analysts clearly believe Minerva Surgical is more favorable than Vivos.

About Vivos

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States and internationally. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.

About Minerva Surgical

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.